Non-invasive prenatal testing (NIPT)

Introducing the Generation® screen

  • Simple

    • A single tube of blood drawn from your arm;
  • Convenient

    • You can have blood collected in one of our collection centres from as early as 10 weeks;
  • Accurate6,7,13

    • >99% Accuracy for Trisomy 21, 18 & 13
  • Australian

    • Your Generation® test is performed in Australia in an accredited laboratory.
      (If a Generation® Plus test is requested, your sample will be sent to an accredited laboratory in California.)
  • Reliable

    • It has the lowest reported test failure rate of any NIPT (<0.1%)6. This rate is also consistent with our experience so far.
  • Fast

    • Your doctor will receive results within 5-7 days from your blood collection for the Generation® test. If your doctor recommends the Generation® Plus test, the results will be available in 9-14 days from collection due to shipping times.
  • Extended Services

    • Exclusively able to be bundled with other advanced scientific services such as cord blood stem cell banking for your baby at birth

As this website contains only general education information, professional advice from your medical practitioner should be sought before applying the information in this website to particular circumstances. You should not rely on any information contained in this website without first obtaining professional advice. Prices are correct at time of publishing and are subject to change without notice.


What is the Generation® non-invasive prenatal test?

How does the Generation® test work?

Why the Generation® test?

What kind of conditions can the Generation® test detect?

How will my test be reported?

Do normal Generation® test results mean that my baby will be perfectly healthy?

Why did we choose the Generation® test?

How do I organise to have the Generation® test?

Does Medicare or private health insurance cover the cost of the Generation® prenatal test?

Contact Us

Call us on
1800 822 999
or email us at
info@genomicdiagnostics.com.au

References

1. Bhatt S, Parsa S, Snyder H, et al. Clinical Laboratory Experience with Noninvasive Prenatal Testing: Update on Clincially Relevant Metrics. ISPD 2014 poster.
2. Bianchi DW, Platt LD, Goldberg JD, et al. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol. 2012;119:890-901.
3. Futch T, Spinosa J, Bhatt S, de Feo E, Rava RP, Sehnert AJ. Initial clinical laboratory experience in non-invasive prenatal testing for fetal aneuploidy from maternal plasma DNA samples. Prenat Diagn. 2013;33:569-574.
4. Bianchi DW, Parker RL, Wentworth J et al. DNA Sequencing versus Standard Prenatal Aneuploidy Screening. N Engl J Med 2014; 370:799-808.
5. Verinata Health, Inc. (2012) Analytical Validation of the verifi Prenatal Test: Enhanced Test Performance For Detecting Trisomies 21, 18 and 13 and the Option for Classification of Sex Chromosome Status. Redwood City, CA.

In addition, clinical best practice guidelines from Australian and international medical societies recommend that all pregnant women, regardless of risk status, be offered the opportunity for discussion and choice regarding NIPT and other available prenatal screening and diagnostic tests.